|
Armored and GPC3-targeted autologous CAR T-cell Clinical Trials
1 actively recruiting trial
No change since May 2026
Also known as: C-CAR031
Pipeline
Phase 1/2: 1
Top Sponsors
- Shanghai AbelZeta Ltd.1
Indications
- Liver Disease1
- Liver Cancer1
- Hepatocellular Carcinoma1
- Cancer1
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.